Recall-plagued J&J pulls two joint products; Lilly wins longer ban on Strattera copies;

@FiercePharma: Price-bound Sanofi may forego Genzyme bid. Article | Follow @FiercePharma

> In its 11th recall in the last 12 months, Johnson & Johnson said its artificial joint business recalled two hip-replacement products because they are prone to early failure. News

> Eli Lilly won a court order extending the ban on generic versions of its attention-deficit treatment Strattera while it appeals a patent ruling. Report

> Europe's drug regulator is reviewing the safety of GlaxoSmithKline's Pandemrix flu vaccine, which has been given to more than 30 million people in Europe, to investigate possible links to a sleep disorder. Story

> Sanofi-Aventis says the FDA accepted for review its application to extend the indication of its Menactra vaccine to infants. Sanofi release | Story

> Swiss drugs industry supplier Lonza expects new products and improved production to add 500 million Swiss francs ($488.3 million) to sales over the next three to four years. Story

Biotech News

 @FierceBiotech: Roche melanoma drug registers striking results. Article | Follow @FierceBiotech

 @JohnCFierce: Cephalon CEO Frank Baldino is taking a temp medical leave of absence, but no word on what ails him. Story | Follow @JohnCFierce

> XenoPort president departs. Story

> Mass. sees jump in biotech jobs. Article

> Roche, Genentech hit with refuse-to-file letter. News

> Stallergenes hunts for U.S. partner. Report

> FDA approves Novartis' combo pill Teklamo. Item

And Finally... If you're wondering about the fate of Ranbaxy Laboratories' ex-chief Malvinder Singh, he's trying to expand Fortis Healthcare, another family company, from a string of Indian hospitals into a pan-Asian healthcare network. Report

Suggested Articles

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.